

### ZN-c3 WEE1 Data Review KOL Event

April 12, 2021

# Forward-Looking Statements and Disclaimer

Zentalis Pharmaceuticals, Inc. ("we," "us," "our," "Zentalis" or the "Company") cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future financial or business performance, plans, prospects, trends or strategies, objectives of management, competition and other financial and business matters, the potential, safety, efficacy, and regulatory and clinical progress of our current and prospective product candidates, plans and timing for the initiation of and release of data from our clinical trials and our ability to meet other key milestones, planned preclinical activities, our current and prospective collaborations, the estimated size of the market for our product candidates, and the timing and success of our development and commercialization of our anticipated product candidates and the market acceptance thereof are forward-looking statements, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; interim, initial, "topline", and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Neither we nor our affiliates, advisors or representatives makes any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation.

Data of Fulvestrant, RAD1901, Abemaciclib, Alpelisib, AZD1775, Venetoclax and Osimertinib presented in this presentation is based on evaluation of comparable proxy chemical compounds purchased from commercial sources rather than the pharmaceutical company commercializing or developing, as applicable, the compound.



# Broad Oncology Pipeline Designed to Improve Patient Outcomes

		IND Enabling	Phase 1/2	Phase 3	Collaborator <sup>(1)</sup>
ZN-c5: Oral SERD	_				加工勝座
Breast Cancer	Monotherapy				<b>シ</b> 正腾康 zentera
DI Edst Calicei	Combinations				Lilly 🤁 Pfizer
ZN-c3: WEE1 Inhib	bitor				
Solid Tumors	Monotherapy				<b>シ</b> 正腾康 zentera
Solid fumors	Combinations				gsk
ZN-d5: BCL-2 Inhil	oitor				
AML or Non-Hodgkin's Lymphoma	Monotherapy				<b>シ</b> 正腾康 zentera
Breast Cancer	Combination with ZN-	-c5			
ZN-e4: EGFR					
NSCLC					SciClone®


(1) Zentalis is currently evaluating ZN-c5 in combination with palbociclib (Ibrance<sup>®</sup>), as part of a clinical research collaboration with Pfizer, evaluating ZN-c5 in combination with abemaciclib (Verzenio<sup>®</sup>), as part of a clinical research collaboration with Pfizer, evaluating ZN-c5 in combination with abemaciclib (Verzenio<sup>®</sup>), as part of a clinical research collaboration with GlaxoSmithKline. Zentalis maintains full ownership of ZN-c3 in each such collaboration. SciClone has development and commercial rights to ZN-e4 in Greater China (including Macau and Hong Kong), South Korea, Taiwan and Vietnam. Zentera, our majority-owned joint venture, has development and commercial rights to ZN-c5, ZN-c3 and ZN-d5 in select Asian countries (including China). Zentera submitted INDs in China for each of ZN-c5 and ZN-c3 and intends to submit an IND in China ZN-d5 in 2021.



# ZN-c3: WEE1 Inhibitor



# ZN-c3: A DNA Damage Response (DDR) Drug Candidate




- WEE1 is a protein kinase expressed at high levels in many cancer types that prevents entry into mitosis in response to DNA damage by regulating the G2 checkpoint
- WEE1 inhibition causes cancer cells to proceed to mitosis without repairing DNA damage, resulting in premature mitotic entry and apoptosis
- ZN-c3 has demonstrated significant growth inhibition and induced apoptosis *in vitro* and anti-tumor activity *in vivo*

zentalis



# WEE1 Inhibitors Show Strong Preclinical Activity and Clinical Responses

Combination of WEE1 and PARP Inhibitors Showed Improved Anti-Tumor Activity Compared to the Use of Each as Monotherapy <sup>(1)</sup> Phase II Study of WEE1 Inhibitor Plus Gemcitabine for Platinum-Refractory Recurrent Ovarian Cancer: Double-Blind, Randomized, Placebo-Controlled<sup>(2)</sup> Phase II Trial of WEE1 Inhibitor in recurrent Uterine Serous Carcinoma (USC) <sup>(3,4)</sup>



(1) Fang, Y. Cancer Cell (2019). A total of 2 x 10<sup>6</sup> OVCAR8 ovarian cancer cells were injected subcutaneously (s.c.) and grown for 2 weeks in nude mice. Mice were randomized with six in each group and treated as indicated. Average tumor volume ± SEM are displayed. p value: one-way ANOVA. \*\*p < 0.01

(2) Lheureux S., Lancet (2021). Addition of a WEE1 to Gemcitabine shows a statistically significant improvement in mOS over Gemcitabine with placebo (HR=0.56, P=0.017)

(3) Liu, J.F. AZD1775 SGO Presentation (2020)

6

(4) An aggressive subtype of endometrial carcinoma characterized by frequent TP53 mutations (>90%)

# ZN-c3: Excellent Potency, PK and Preclinical Activity

### ZN-c3 Anti-Proliferative Activity in a Panel of Cell Lines


Compound	CTG IC <sub>50</sub> (nM)								
ID	NS	NSCLC		SCLC		ТИВС		Ovarian cancer cells	
	NCI-H23	A-427	DMS-53	NCI- H1048	MDA- MB-231	HCC 1806	OVCAR3	UWB 1.289	
ZN-c3	124	88	118	92	190	95	69	54	
AZD1775 <sup>(1)</sup>	108	94	130	97	233	94	124	57	

### **Improved Tumor Concentration in Preclinical Models**

Study (A-427 NSCLC)	ZN-c3			A	ZD1775	(1)
Dose (mg/kg/day)	20	40	80	20	40	80
C <sub>max</sub> (ng/mL)	1,167	1,997	5,100	635	2,460	4,703
T <sub>max</sub> (hr)	1	1	1	1	1	1
AUC <sub>0-24hr</sub> (ng·hr/mL)	4,863	17,088	39,722	1,494	6,313	13,408
Tumor Conc. (ng/mL)	10.5	48.0	811	BQL <sup>(2)</sup>	BQL	6.95

### ZN-c3 Induced Prolonged Tumor Growth Delay

A427 Human NSCLC Tumor Xenograft Model



(1) AZD1775 data based on evaluation of comparable proxy chemical compound purchased from commercial sources rather than obtained from the pharmaceutical company developing the compound.


(2) BQL: Below Quantifiable Level


7

Note: ZN-c3 has excellent thermodynamic solubility of 2132 µM (vs. 60 µM for AZD1775) based on internal data



# ZN-c3: Differentiated Selectivity Profile in >470 Kinase Screening Panel





(1) AZD1775 data based on evaluation of comparable proxy chemical compound purchased from commercial sources rather than obtained from the pharmaceutical company developing the compound

8 (2) Illustrations reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)



## ZN-c3: Comprehensive Clinical Development Plan

### **Ongoing and Planned Clinical Programs**

Phase 1

Solid Tumors: Monotherapy Dose Escalation Initial data presented at AACR 2021

Ovarian Cancer Chemo Combination Ph 1b Study Initiated 4Q 2020

Osteosarcoma ZN-c3 + gemcitabine Ph 1/2 Study Expected Initiation 3Q 2021

Ovarian Cancer ZN-c3 + niraparib Ph 1/2 Study Expected Initiation 2H 2021

# Phase 2Uterine Serous Carcinoma<br/>Monotherapy Ph 2 Study<br/>Expected Initiation 3Q 2021Additional Clinical Studies

Monotherapy Study Combination Study

### **Overview**


- Initial Phase 1 monotherapy dose escalation data reported at AACR 2021
- ZN-c3 was safe and welltolerated as a single agent
- RP2D for ZN-c3 determined
- ZN-c3 showed Exceptional Responses in heavily pretreated subjects with advanced solid tumors
- Corresponding studies with Zentera in Greater China



# Initial Results of ZN-c3 Phase 1 Monotherapy Dose Escalation Trial



# ZN-c3 Study: Schema and Endpoints



### **Study Objectives include:**

- Safety and tolerability of ZN-c3, determination of maximum tolerated dose (MTD) based on a CRM model, and recommended Phase 2 dose (RP2D)
- Clinical activity according to RECIST v 1.1: ORR, DOR, PFS, CBR
- Plasma pharmacokinetics (PK) of ZN-c3
- Evaluation of exploratory biomarkers



### **Key Inclusion:**

- Subjects must have a solid tumor with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Measurable or evaluable disease per RECIST version 1.1

### **Key Exclusion:**

- Major surgery within 28 days, radiation therapy within 21 days, stem cell transplant within 3 months, or serious illness/medical condition
- Hypersensitivity to any drugs similar to ZN-c3, or prior therapy with a WEE1 inhibitor




# ZN-c3 Study: Dose Cohorts, Dose Frequency, Number of Subjects Enrolled and Cancer Types (as of 02/12/2021)

#### Dosing Cohorts, Gender and Cancer Type

ZN-c3 Dose in mg	Males	Females	Cancer Types (Primary)
25 QD	0	2	Lung (2)
50 QD	1	1	Breast, Colon
75 QD (Expansion Cohort)	5	5	Bladder, Breast (2), Colon (3), Endometrium, Gall Bladder, Pancreas, Prostate
100 QD	3	1	Breast, Prostate (2), Testis
200 QD	1	2	Endometrial Serous Carcinoma, Rectum, Prostate
300 QD (Expansion Cohort)	6	6	Ampulla of Vater, Breast, Colon (2), Kidney, Lung, Ovary, Prostate (2), Retroperitoneum, Uterus (2)
175 BID	2	4	Ampullary Invasive, Breast, Colon, Ovary, Pancreas, Prostate
350 QD	3	3	Colon (2), Gastric (2), Pancreas, Uterus
400 QD	2	1	Biliary Tract, Colon, Pancreas
450 QD	3	1	Colon (2), Lung, Uterus
450 QD Ramp Up	1	2	Lung, Pancreas, Prostate

### Dosing Cohorts, Frequency and # of Subjects





### Monotherapy Responses for Representative Agents

### **Untargeted**, All-Comer

- AZD1775 (WEE1 inhibitor)
- Metastatic Solid Tumor study
- N=21
- 2 PRs (9.5%)<sup>(1)</sup>
   Responses only in BRCA mutants

### Average Expected Response Rates = 6.5%<sup>(2)</sup>

### **Targeted**


- Larotrectinib (Trk inhibitor)
- Metastatic Solid Tumor study
- 8/8 PRs (100%) in NTRK fusion<sup>(3)</sup>
- Zero responses in 62 patients (0%) who were NTRK-

Expected Response Rates = 18-78%<sup>(4)</sup>

- (1) Do Kh et al. Journal of Clinical Oncology. 2015
- (2) Chakiba C et al. Journal of Clinical Oncology. 2016
- (3) Hong DS et al. Annals of Oncology. 2019
- (4) Gyawali B et al. JNCCN. 2020



# ZN-c3 Study: Initial Waterfall Plot (Updated 03/01/2021)



zentalis

(1) 3 subjects with no treatment scans (CRC, USC, Pancreas), and experienced clinical progressive disease (CPD). + denotes treatment ongoing

(2) 3 confirmed Exceptional Responders PRs, including an additional confirmation of Exceptional Responder PR since AACR Presentation Press Release

(3) Updated as of 03/15/2021

### ZN-c3 Study: Exceptional Responders on Single Agent ZN-c3

### **Initial Results from ZN-c3 Study**

- Preliminary evidence of rapid, single agent clinical activity in heavily pretreated patients generating Exceptional Responses
- PRs also in tumor types not expected with WEE1 monotherapy (e.g., non-USC or BRCA1/2 WT patients)
- At the time of the data cutoff on March 1, 2021, 5 subjects with best overall response of Partial Response (PR) by RECIST v1.1:
  - 3 confirmed Exceptional Responder PRs<sup>(1)</sup> in multiple tumor types (ovarian cancer, CRC, NSCLC)
  - 2 unconfirmed PRs in USC
- RP2D 300mg QD with continuous dosing

Exceptional Responses were observed in non-USC patients who had experienced up to 18 prior lines of treatment and no recent responses



# Exceptional Responders: Who Are They?

### Who is an Exceptional Responder?



JNCI J Natl Cancer Inst (2021) 113(1): djaa061

doi: 10.1093/jnci/djaa061 First published online April 27, 2020 Article

#### The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

Barbara A. Conley, MD <sup>(i)</sup> Lou Staudt, MD, PhD,<sup>2</sup> Naoko Takebe, MD, PhD,<sup>3</sup> David A. Wheeler, PhD,<sup>4</sup> Linghua Wang, PhD <sup>(i)</sup>, <sup>5</sup> Maria F. Cardenas, BS,<sup>4</sup> Viktoriya Korchina, MS,<sup>4</sup> Jean Claude Zenklusen, PhD,<sup>2</sup> Lisa M. McShane, PhD <sup>(i)</sup>, <sup>1</sup> James V. Tricoli, PhD,<sup>1</sup> Paul M. Williams, PhD,<sup>6</sup> Irina Lubensky, MD,<sup>1</sup> Geraldine O'Sullivan-Coyne, MD,<sup>3</sup> Elise Kohn, MD,<sup>1</sup> Richard F. Little, MD,<sup>1</sup> Jeffrey White, MD,<sup>1</sup> Shakun Malik, MD <sup>(i)</sup>, <sup>1</sup> Lyndsay N. Harris, MD,<sup>1</sup> Bhupinder Mann, MD,<sup>1</sup> Carol Weil, JD,<sup>1</sup> Roy Tarnuzzer, PhD <sup>(i)</sup>, <sup>2</sup> Chris Karlovich, PhD <sup>(i)</sup>, <sup>6</sup> Brian Rodgers, MD,<sup>1</sup> Lalitha Shankar, MD, PhD,<sup>1</sup> Paula M. Jacobs, PhD <sup>(i)</sup>, <sup>1</sup> Tracy Nolan, BE <sup>(i)</sup>, <sup>7</sup> Sean M. Berryman, MA,<sup>7</sup> Julie Gastier-Foster, PhD,<sup>8</sup> Jay Bowen, MS <sup>(i)</sup>, <sup>8</sup> Kristen Leraas, MS,<sup>8</sup> Hui Shen, PhD,<sup>9</sup> Peter W. Laird, PhD <sup>(i)</sup>, <sup>9</sup> Manel Esteller, MD, PhD <sup>(i)</sup>, <sup>10</sup> Vincent Miller, MD,<sup>11</sup> Adrienne Johnson, MS,<sup>11</sup> Elijah F. Edmondson, DVM, PhD <sup>(i)</sup>, <sup>12</sup> Thomas J. Giordano, MD,<sup>13</sup> Benjamin Kim, MS,<sup>1</sup> S. Percy Ivy, MD <sup>(i)</sup>.\*

<sup>1</sup>Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA, <sup>2</sup>Center for Cancer Genomics, National Cancer Institute, Bethesda, MD, USA, <sup>3</sup>Center for Cancer Genomics, National Cancer Institute, Bethesda, MD, USA, <sup>4</sup>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA, <sup>5</sup>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>4</sup>Tederick National Laboratory for Cancer Research, Frederick, MD, USA, <sup>5</sup>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA, <sup>4</sup>Nationwide Children's Hospital, Columbus, OH, USA, <sup>4</sup>Van Andel Research Institute, Grand Rapids, MJ, USA, <sup>4</sup>Yan Andel Research, Frederick National Laboratory for Gancer Research, Frederick, MD, USA and <sup>4</sup>Department of Pathology, University of Michigan, Ann Arbor, MI, USA

"NCI selected those that fit specific criteria [for an Exceptional Responder]: The patient's tumors shrank or disappeared in response to a drug that worked for less than 10% of patients overall in a clinical trial. Or the patient had a response that lasted at least three times longer than it had for a typical patient."

- Harold Varmus, Weill Cornell Medicine

### **Characteristics of an Exceptional Response**


- Unexpected
- Rapid
- Durable

Exceptional Responses are generally observed randomly, and the underlying driver of response is often unknown



# Exceptional Responders Exhibit Unique Biological Features

### Zentalis Predictive Biomarker Approach




#### Confirming Biomarker Profile

- Zentalis has observed, at this initial stage of the ZN-c3 study at the time of the data cutoff on March 1, 2021, multiple Exceptional Responses on single agent ZN-c3 (3/3 patients or 100% ORR)
- Activity in tumor types (e.g., CRC) not previously seen by other WEE1 inhibitors
- In addition: Partial Responses seen in USC patients
- Zentalis Predictive Biomarker approach used to confirm unique, novel and predictive profile



# Summary of Relevant Genomic Backgrounds





### Exceptional Responder #1: First PR seen in ≥3 lines

### **Exceptional Responder #1 Summary**

- 63-year-old White male, Stage IV CRC, metastases to the liver, lymph nodes, and pleura. ECOG PS 1
- Heavily pretreated with 5 prior lines of therapy (see table)
- ZN-c3 starting dose: 450 mg QD on August 18<sup>th</sup>, 2020
  - Dose reduced to 300 mg QD on D32 due to Gr 3 neutropenia, then 200 mg QD (5/2) on D77 due Gr 2 nausea, vomiting and Gr 1 diarrhea
- TP53 mutant. BRCA1/2 negative. CCNE1 amp negative
- Duration on study: 169 days (5.6 months), off study now due to progressive disease

Confirmed PR with 51% reduction overall (updated 03/01/21); First PR seen in ≥3 lines


### **Previous Therapy Experience**

Intent of Treatment	Regimen	Start	Stop	Best response
Advanced /	Bev / 5FU / LV	20/Jun/2018	28/May/2019	Unknown
Metastatic				
Advanced /	Irinotecan /	24/Jul/2019	31/Dec/2019	Unknown
Metastatic	5FU / LV / Bev			
Advanced /	MK0482	30/Jan/2020	12/Mar/2020	PD
Metastatic				
Advanced /	ABBV181 /	15/Apr/2020	13/May/2020	PD
Metastatic	ABBV151		27/May/2020	
Advanced /	AGEN2373	1/Jul/2020	1/Jul/2020	PD
Metastatic				

Bev: Bevacizumab, 5FU: Fluorouracil, LV: Leucovorin, PD: Progressive disease AGEN2373: anti-CD137 AB, ABBV181: PD-1 inhibitor, ABBV151: GARP- TGF- $\beta$ 1 MAB




# Exceptional Responder #1: Unexpected, Dramatic and Durable Decrease of Tumor Marker within Weeks of First ZN-c3 Administration



- CEA tumor marker typically used in CRC
- Patient experienced rapid CEA decrease from 327 ng/mL at baseline to <50 ng/mL within 3 weeks of initiation of ZN-c3
- Tumor marker level remained down for ~6mos

# Exceptional Responder #1: Baseline and Follow-up Liver Imaging and Tumor Markers with 51% Partial Response (Updated 03/01/21)



Baseline: 07/30/2020

1<sup>st</sup> Assessment: 10/09/2020



# Exceptional Responder #2: Experienced 18 prior lines and first response seen in over two years with ZN-c3

### **Exceptional Responder #2 Summary**


- 72-year-old White female, Stage IV ovarian cancer, metastases to the pleura, peritoneum and retroperitoneum. ECOG PS 1
- Heavily pretreated with 18 prior lines of therapy, 11 of which were in the advanced/metastatic setting (see table)
- ZN-c3 starting dose: 175 mg BID on October 7th, 2020
  - Dose was reduced to 300 mg QD on D13 due to Gr 3 diarrhea and Gr 2 dehydration, further modified to 200 mg QD (5/2) on D69 due to persistent Gr 1-2 dizziness Tolerating 5 days on 2 days off weekly
- CA-125 dropped from 610 kU/L at baseline to 125 kU/L within 4 weeks after first dose and <u>normalized 3 weeks later</u>
- TP53 mutant. BRCA1/2 negative. CCNE1 amp positive
- Duration on study. 186 days (6.2 months) and remains on study

Confirmed PR with 65% reduction overall (updated 03/01/21) with 18 prior lines and first response seen in over two years; Remains on study

Intent of Treatment	Regimen	Start	Stop	Best Response
Adjuvant	Carboplatin / Paclitaxel	8/Sep/2011	10/Nov/2011	Unknown
Adjuvant	Letrozole	27/Apr/2012	25/Oct/2013	PD
Adjuvant	Carboplatin / Paclitaxel	7/Nov/2013	20/Feb/2014	SD
Adjuvant	Carboplatin / Taxol	17/Apr/2014	29/May/2014	Unknown
Adjuvant	Zejula	UNK/UNK/20 14	20/Jul/2014	Unknown
Adjuvant	Arimidex	20/Mar/2015	5/Jun/2015	Unknown
		Total 18 Prior Lin	nes	
Advanced / Metastatic	APG115 (MDM2 inh) / Pembrolizum ab	27/Feb/2019	05/Aug/2019	SD
Advanced / Metastatic	ABBV-155 (CD275 ADC)	09/Sep/2019	09/Sep/2019	PD
Advanced / Metastatic	NC318 (Siglec-15 AB)	16/Oct/2019	23/Dec/2019	SD
Advanced / Metastatic	SM08502 (CLK inhibitor)	13/Feb/2020	9/Apr/2020	PD




# Exceptional Responder #2: Unexpected, Dramatic and Durable Decrease of Tumor Marker within Weeks of First ZN-c3 Administration



- CA-125 tumor marker typically used in ovarian cancer
- CA-125 dropped from 610 kU/L at baseline to 125 kU/L within 4 weeks after first dose and <u>normalized 3 weeks later</u>
- Patient remains on study and tumor marker remains down



### Exceptional Responder #2: Baseline and Follow-up Porta Hepatis Lymph Node; Overall 65% Partial Response (Updated 03/01/21)




Baseline: 09/22/2020

1<sup>st</sup> Assessment: 11/24/2020



# Exceptional Responder #2: Baseline and Follow-up Pleural Lesion with Complete Regression





# Exceptional Responder #3: No responses seen prior to ZN-c3

### **Exceptional Responder #3 - Summary**

- 61-year-old White male, Stage IV NSCLC, metastases to lung, liver, ECOG PS 0
- 3 prior lines of therapy in the advanced/metastatic setting
- ZN-c3 starting dose: 350 mg QD on November 17<sup>th</sup>, 2020, no dose reduction
- TP53 mutant. BRCA1/2 negative. CCNE1 amp negative
- Duration on study: 145 days (4.8 months) and remains on study


Confirmed PR with 50% reduction overall at first evaluation; Remains on study

### **Previous Therapy Experience**

Intent of Treatment	Regimen	Start	Stop	Best Response
Neoadjuvant	Carboplatin/ Paclitaxel	27/Nov/2018	05/Feb/2019	SD
Adjuvant	Durvalumab	UNK/Feb/2019	UNK/Jul/2019	PD
Advanced / Metastatic	Carboplatin/ Pemetrexed	UNK/Jul/2019	23/Oct/2019	PD
Advanced / Metastatic	Atezolizumab	UNK/Jan/2020	UNK/Mar/2020	PD
Advanced / Metastatic	Docetaxel	UNK/Apr/2020	20/Sep/2020	PD



### Exceptional Responder #3: Baseline and Follow-up Lung Mass Imaging with 50% Partial Response



Baseline: 11/10/2020

1<sup>st</sup> Assessment: 01/18/2021



# USC Partial Response #1

### **USC Partial Response #1 - Summary**

- 72-year-old, White female, Stage IV USC; metastases to peritoneum and lymph nodes, ECOG PS 1
- 1 prior line of therapy in the advanced/metastatic setting
- Starting dose: 350 mg QD on December 9th, 2020
  - Dose reduced to 300 mg QD on D55 due to Gr 3 fatigue
- Tumor marker CA 125:
  - December 8th, 2020: 35.8 U/mL
  - February 10th, 2021: 16 U/mL
- TP53 mutant. BRCA1/2 negative. CCNE1 amp negative

Unconfirmed PR of 49%; Remains on Study

### **Previous Therapy Experience**

Intent of Treatment	Regimen	Start	Stop	Best Response
Adjuvant	Carboplatin / Paclitaxel	10/Dec/2018	27/Mar/2019	Unknown
Advanced / Metastatic	Paclitaxel / Avastin	06/Dec/2019	27/Mar/2020	Unknown
Maintenance	Avastin	24/Apr/2020	30/Oct/2020	Unknown



# USC Partial Response #2

### **USC Partial Response #2 - Summary**

- 69-year-old, African American female, Stage IV USC, metastases to lymph node and lung, ECOG PS 1
- 4 prior lines of therapy in the advanced/metastatic setting
- Starting dose: 300 mg QD on January 13<sup>th</sup>, 2021
  - Dose modified to 300 mg QD (5/2) on D44 due to Gr 2 nausea
  - Further reduced to 200 mg QD on D51 due to Gr 2 fatigue, nausea and anorexia
- Tumor marker CA-125:
  - Baseline: 440.4 U/mL
  - D63: 46.4 U/mL
- TP53 mutant. BRCA1/2 negative. CCNE1 amp negative


Unconfirmed PR of 43%, Remains on Study

### **Previous Therapy Experience**

Intent of Treatment	Regimen	Start	Stop	Best Response
Advanced / Metastatic	Carboplatin / Taxol / Avastin	13/Sep/2019	22/Nov/2019	PD
Advanced / Metastatic	Trastuzumab (Herceptin)	24/Feb/2020	07/Apr/2020	PD
Advanced / Metastatic	Pembrolizumab / Lenvatinib	30/Apr/2020	21/May/2020	PD
Advanced / Metastatic	Doxorubicin Liposomal	24/Jun/2020	12/Nov/2020	PD



# RP2D Shows Highest AUC Between 25 mg and 400 mg Doses



- Greater than dose proportional exposure up to 450 mg (not plotted)
- 1.87 to 2.50-fold accumulation at 200-350 mg dose
- No additional increase of exposure occurs beyond Day 15 (up to Cycle 6)
- ZN-c3 shows ~30% more exposure than AZD1775 300 mg dose<sup>(1)</sup>



# Decreases in p-CDK1 Show Target Engagement for WEE1 Inhibition

1. CDK1 phosphorylation by WEE1


2. p-CDK1 inhibition

ZN-c3


WEE1

### Confirmation of WEE1i Target Engagement in Surrogate Tissue

- 1. CDK1 phosphorylation (p-CDK1) is mediated by WEE1
- 2. Inhibition of WEE1 therefore will lead to inhibition of p-CDK1
- 3. Skin biopsies were performed at baseline (C1D1) and ontreatment (C1D15) to verify p-CDK1 levels, and hence level of target engagement of WEE1




# PK/PD Correlation Shows Active Target Engagement at RP2D



- Inhibition of p-CDK1
  - demonstrates WEE1 target engagement
  - Increase in dose / drug exposure directly relates to WEE1 target engagement
  - Data supportive of RP2D




# Interim Adverse Events (≥3 events) of All Patients (as of 02/12/2021)





# Interim AEs (all events): ZN-c3 ≥300 mg versus Adavosertib 300 mg<sup>(1)</sup>




Source: Liu JF et al. J Clin Oncol. 2021 Mar 11: JCO2003167

35

(1) Non-head-to-head comparison. Results of a head-to-head comparison may differ significantly from those set forth herein. In addition, because our Phase 1 clinical trial for ZN-c3 and the Adavosertib clinical trials were separate trials, differences between the results of the trials may not be statistically or clinically meaningful



# ZN-c3 Exhibits Meaningfully Reduced Hematological Toxicities versus Adavosertib<sup>(1)</sup>



Despite continuous dosing delivering twice the drug load, ZN-c3 <u>induces markedly less</u> hematological toxicity

Source: Liu JF et al. J Clin Oncol. 2021 Mar 11: JCO2003167

36 (1) Non-head-to-head comparison. Results of a head-to-head comparison may differ significantly from those set forth herein. In addition, because our Phase 1 clinical trial for ZN-c3 and the Adavosertib clinical trials were separate trials, differences between the results of the trials may not be statistically or clinically meaningful



# Other ZN-c3 Studies




## ZN-c3 Phase 2 Monotherapy Study in USC

### **Overview of Uterine Serous Carcinoma (USC)**

- Type II endometrial cancer
- Not hormonally mediated
- Approx. 70% of USC present with Stage III or IV disease at diagnosis
- Poor survival rates; only 30-50 %, even if confined to uterus
- >90% of USCs have TP53 mutation
- Recurrence rates are 29-80% post-surgery
- ~6k new cases and ~4.5k deaths in U.S. per year
- Current standard of care: comprehensive surgery, adjuvant chemotherapy and adjuvant vaginal cuff brachytherapy

### **USC Represents High Unmet Medical Need**


#### Comprises 10% of Endometrial Cancers with Highest Mortality




#### Zentalis Initiating Phase 2 Monotherapy Trial for Patients with USC in 3Q 2021



# ZN-c3 + Gemcitabine: Novel Combination Approach for Osteosarcoma





#### **Clinical Unmet Need in Osteosarcoma**

- Approximately 1,000 new cases in the US<sup>(1)</sup>
- Up to 90% have sequence mutations or structural variants in TP53 and are often enriched in relapsed or refractory cases, portending resistance to chemotherapy<sup>(2)</sup>
- No significant advances over the last 10 plus years<sup>(3)</sup>
- Overall survival rate for patients with metastatic or recurrent disease is <20%<sup>(4)</sup>

20

Anticipated Phase 1/2 Start in 3Q 2021

- (1) American Cancer Society. Last accessed on April 7<sup>th</sup>, 2020
- (2) Tang et al. J Orthop Res. 2019;37(3):789–98.
- (3) Misaghi A et al. *Sicot-j*. 2018;4:12.
- 39 (4) Harrison DJ et al. *Expert Rev Anticanc.* 2018;18:1, 39-50



# ZN-c3 + Zejula (niraparib) Collaboration with GSK



#### Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer

NEW YORK & SAN DIEGO, April 12, 2021 -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a clinical collaboration agreement with GlaxoSmithKline ("GSK") in which Zentalis will evaluate the combination of ZN-c3, Zentalis' oral WEE1 inhibitor product candidate, and ZEJULA (niraparib), GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with advanced epithelial ovarian cancer. Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies.

"This clinical collaboration and supply agreement with GSK allows us to investigate the broader potential of our WEE1 inhibitor when used as part of a combination treatment with niraparib, a PARP inhibitor," commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals. "As demonstrated in our preclinical studies, ZN-c3 is designed to have significant advantages over other investigational WEE1 inhibitor therapies. We believe this combination has the potential to meaningfully improve the outcomes for patients with ovarian cancer."

PARP inhibitors prevent DNA damage repair in cancer cells. Similar to PARP, WEE1 plays a role in cellular regulation and repair, allowing cells with DNA damage to repair and survive. Inhibition of WEE1 causes dysregulation of DNA replication and subsequently induces apoptosis. Based on these complementary mechanisms of action, the use of WEE1 and PARP inhibitors could potentially have synergistic anti-tumor activity.

More than 300,000 women worldwide are diagnosed with ovarian cancer each year, leading to over 180,000 fatalities<sup>1</sup>. While substantial progress has been made in the treatment of this disease, there is an urgency to address the remaining unmet need through the development of innovative combination treatments.

Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study with GSK providing all required doses of niraparib. Zentalis maintains full ownership of ZN-c3.

<sup>1</sup>www.cancerresearch.org

#### **Zentalis and GSK Collaboration Agreement**

- Announced April 12, 2021
- Zentalis will evaluate the combination of WEE1 inhibition (ZN-c3) and PARP inhibition (niraparib) in patients with advanced epithelial ovarian cancer
- ZN-c3's tolerability profile shows promise for future combinations with niraparib and other drugs
- Zentalis/Zentera retain full ownership of ZN-c3
- Details of the study will be disclosed on <u>www.clinicaltrials.gov</u>


#### Initiating Phase 1b in 2H 2021



# ZN-c3 Market Opportunities



# Versatility of WEE1 Inhibition Could Unlock Large Addressable Populations Across Solid Tumors



42 (1) Gynecologic Oncology 115 (2009) 142-153, David Boruta et al.; National Cancer Institute, SEER 2020 Data

# ZN-c3 Summary

- ZN-c3 has strong evidence for clinical activity: Exceptional Responders in heavily pretreated populations, as well as PRs in USC patients
- ZN-c3 appeared safe and well-tolerated with a wide therapeutic window
- Zentalis declared RP2D with continuous (not intermittent) dosing at 300 mg QD
- Zentalis confirming Unique Predictive Biomarker for the Exceptional Responder patient population
- ZN-c3 may offer treatment to diverse solid tumor indications:



ZN-c3 has the Potential to be Best-in-Class WEE-1 Inhibitor in the Clinic



# Questions?



# Key Milestones

	Event	Expected Timing	Event	Expected Timing
	ZN-c5 (Oral SERD)		ZN-d5 (BCL-2 Inhibitor)	
	<ul> <li>Phase 1 topline results from monotherapy dose escalation study</li> <li>Initiate Phase 1b combination study with abemaciclib</li> </ul>	<ul> <li>Achieved July '20</li> <li>Achieved 4Q '20</li> </ul>	<ul> <li>IND Clearance</li> <li>Initiate Phase 1 trial in AML and Non-Hodgkin's Lymphoma</li> </ul>	<ul> <li>April '20</li> <li>Achieved 4Q '20</li> </ul>
	<ul> <li>Phase 1 topline results from Window of Opportunity study</li> <li>Initiate Phase 2 monotherapy study</li> </ul>	1H 2021	<ul><li>ZN-e4 (EGFR Inhibitor)</li><li>Initial results from dose escalation study</li></ul>	<b>2</b> 021
	<ul> <li>Initiate Phase 2 monotherapy study</li> <li>Initiate Phase 2 combination study with palbociclib</li> </ul>	<ul><li>1H 2021</li><li>1H 2021</li></ul>	Evaluate potential for use in combinations for treatment of lung cancer	2021+
	Initiate Phase 1b combination study with ZN-d5	2021	Integrated Discovery Engine	A
1	Initiate Phase 2/3 monotherapy in earlier-stage patients	<b>2021</b> <sup>(1)</sup>	Submit 5 <sup>th</sup> IND	2021
ų	ZN-c3 (WEE1 Inhibitor)		Zentera	
	<ul> <li>Initiate Phase 1b combination dose escalation study with chemotherapy in ovarian cancer</li> </ul>	Achieved 4Q '20	✓ Submit ZN-c5 and ZN-c3 INDs in China	Achieved 1Q '21
	Phase 1 initial results from dose escalation study in advanced solid tumors	AACR 2021	Submit ZN-d5 INDs in China	2021
	Initiate Phase 2 monotherapy in uterine serous carcinoma	3Q 2021		
	Initiate Phase 1/2 chemotherapy combo in osteosarcoma	3Q 2021		
45	Initiate Phase 1/2 niraparib combo in ovarian cancer	2H 2021	✓ Achievements	zentalis

### Contact Us

Anthony Sun, M.D., CEO and Chairman asun@zentalis.com (212) 433-3780 Melissa Epperly, CFO mepperly@zentalis.com (215) 290-7271

Corporate OfficeScience Center530 Seventh Ave10835 Road to the CureSuite 2201Suite 205New York, NY 10018San Diego, CA 92121



